Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$1.80 USD
-0.08 (-4.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ATNM 1.80 -0.08(-4.26%)
Will ATNM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATNM
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
Other News for ATNM
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Actinium Pharmaceuticals: Phase 3 SIERRA results of Iomab-B published in JCO
Perspective gets FDA fast track status for radiopharmaceutical VMT01
Perspective gets FDA fast track status for radiopharmaceutical VMT101
Novartis expands U.S. radiopharma production amid rising competition